Functional Genetics And Genomics Of Drug Addiction (R03)
National Institutes of Health · Opportunity PA-07-168
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
Purpose. Genetic and genomic studies have identified genes and gene variants that potentially modulate the fundamental biological mechanisms underpinning addictive processes. Discovery of these genes/variants, while extremely valuable, is only a first step in understanding molecular mechanisms of addiction. This Funding Opportunity Announcement encourages basic functional genomic research in two areas: 1. functional validation to determine which candidate genes/variants have an authentic role in addictive processes, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in addiction. Mechanism of Support. This FOA will utilize the NIH Small Research Grant (R03) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-07-166, that solicits applications under the RO1 mechanism and PA-07-167, that solicits applications under the R21 mechanism. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. The R03 is not renewable. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Budget and Project Period. Budgets for direct costs of up to $50,000 per year and a project duration of up to two years may be requested for a maximum of $100,000 direct costs over a two-year project period.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |